Pegfilgrastim to support CHOP-14 in elderly patients with non-Hodgkin's lymphoma

Leukemia and Lymphoma

Volumn 47, Issue 11, 2006, Pages 2344-2350

  Wolf, Max ^a   Bentley, Mark ^b   Marlton, Paula ^b   Horvath, Noemi ^c   Lewis, Ian D ^c   Spencer, Andrew ^d   Herrmann, Richard ^e   Arthur, Chris ^f   Durrant, Simon ^g   van Kerkhoven, Marilyn ^h   MacMillan, Jamie ^h   Mrongovius, Robert ^h  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b PRINCESS ALEXANDRA HOSPITAL   (Australia)

^c ROYAL ADELAIDE HOSPITAL   (Australia)

^d ALFRED HOSPITAL   (Australia)

^e ROYAL PERTH HOSPITAL   (Australia)

^f ROYAL NORTH SHORE HOSPITAL   (Australia)

^g ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^h Amgen Australia Pty Ltd   (Australia)

Author keywords

CHOP 14; Elderly; G CSF; Mobilization; Non Hodgkin's lymphoma; Pegfilgrastim

Indexed keywords

ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; CD34 ANTIGEN; CIPROFLOXACIN; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; FLUCONAZOLE; PREDNISONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; VINCRISTINE;

ADULT; AGE DISTRIBUTION; AGED; ANEMIA; ARTICLE; BLOOD CELL COUNT; BLOOD TOXICITY; BONE PAIN; CANCER PATIENT; CELLULITIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; FEBRILE NEUTROPENIA; FEMALE; GASTROINTESTINAL TOXICITY; GERIATRIC PATIENT; HUMAN; INTESTINE PERFORATION; MALE; NEUROTOXICITY; NEUTROPENIA; NONHODGKIN LYMPHOMA; PATIENT ASSESSMENT; PNEUMOCYSTOSIS; PRIORITY JOURNAL; SEPSIS; THROMBOCYTOPENIA;

AGED; ANTIGENS, CD34; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; FEMALE; FILGRASTIM; HUMANS; LEUKOCYTE COUNT; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; NEUTROPHILS; PREDNISONE; TREATMENT OUTCOME; VINCRISTINE;

EID: 33751080357     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190600881017     Document Type: Article

References (23)

1. Ries, L and Kosary, C and Hankey, B and (1999) SEER Cancer Statistics Review, 1973-1996. Bethesda MD: National Cancer Institute.
2. Gómez, H and Mas, L and Casanova, L and (1998) Elderly patients with aggressive non-Hodgkin's lymphoma treated with CHOP chemotherapy plus granulocyte-macrophage colony-stimulating factor: Identification of two age subgroups with differing hematologic toxicity J Clin Oncol, 16, pp. 2352-2358.
3. Lyman, G and Kuderer, N and Balducci, L. (2002) Cost-benefit analysis of granulocyte colony-stimulating factor in the management of elderly cancer patients Curr Opin Hematol, 9, pp. 207-214.
4. Repetto, L and Balducci, L. (2002) A case for geriatric oncology Lancet Oncol, 3, pp. 289-297.
5. Repetto, L and Biganzoli, L and Koehne, C and (2003) EORTC cancer in the Elderly Task Force guidelines for the use of colony-stimulating factors in elderly patients with cancer Eur J Cancer, 39, pp. 2264-2272.
6. McKelvey, E and Gottleib, J and Wilson, H and (1976) Hydroxydaunomycin (Adriamycin) combination chemotherapy in malignant lymphoma Cancer, 38, pp. 1484-1493.
7. Coltman, C and Dahlberg, S and Jones, S and (1988) SWOG studies in diffuse large cell lymphoma: A subset analysis. In Cancer chemotherapy: Challenges for the future. (pp. 194-202). Tokyo: Excerpta Medica.
8. Fisher, R and Gaynor, E and Dahlberg, S and (1993) Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma N Engl J Med, 328, pp. 1002-1006.
9. Cooper, I and Wolf, M and Robertson, T and (1994) Randomized comparison of MACOP-B with CHOP in patients with intermediate-grade non-Hodgkin's lymphoma. The Australian and New Zealand Lymphoma Group J Clin Oncol, 12, pp. 769-778.
10. Kouroukis, C and Browman, G and Esmail, R and Meyer, R. (2002) Chemotherapy for older patients with newly diagnosed, advanced-stage, aggressive-histology non-Hodgkin lymphoma: A systematic review Ann Intern Med, 136, pp. 144-152.
11. Norton, L. (1997) Evolving concepts in the systemic drug therapy of breast cancer Semin Oncol, 24(4 Suppl 10), pp. S10-3-S10-10.
12. Pfreundschuh, M and Truemper, L and Kloess, M and (2004) Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: Results of the NHL-B2 trial of the DSHNHL Blood, 104, pp. 634-641.
13. Green, M and Koelbl, H and Baselga, J and (2003) A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy Ann Oncol, 14, pp. 29-35.
14. Cheson, B and Horning, S and Coiffier, B and (1999) Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas J Clin Oncol, 17, pp. 1244-1253.
15. Clopper, C and Pearson, E. (1934) The use of confidence or fiducial limits illustrated in the case of the binomial Biometrika, 26, pp. 404-413.
16. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. (1993) A predictive model for aggressive non-Hodgkin's lymphoma N Engl J Med, 329, pp. 987-994.
17. Osby, E and Hagberg, H and Kvaloy, S and (2003) CHOP is superior to CNOP in elderly patients with aggressive lymphoma while outcome is unaffected by filgrastim treatment: Results of a Nordic Lymphoma Group randomized trial Blood, 101, pp. 3840-3848.
18. Gregory, S and Case, D, Jr and Bosserman, L and (2003) Fourteen-day CHOP supported with granulocyte colony-stimulating factor in patients with aggressive non-Hodgkin's lymphoma: Results of a phase II study Clin Lymphoma, 4, pp. 93-98.
19. Yu, J and Leisenring, W and Bensinger, W and (1999) The predictive value of white cell or CD34+ cell count in the peripheral blood for timing apheresis and maximizing yield Transfusion, 39, pp. 442-450.
20. Crawford, J. (2003) Once-per-cycle pegfilgrastim (Neulasta) for the management of chemotherapy-induced neutropenia Semin Oncol, 30(4 Suppl 13), pp. 24-30.
21. Armitage, J and Potter, J. (1984) Aggressive chemotherapy for diffuse histiocytic lymphoma in the elderly: Increased complications with advancing age J Am Geriatr Soc, 32, pp. 269-273.
22. Donnelly, G and Glassman, J and Long, C and (2000) Granulocyte-colony stimulating factor (G-CSF) may improve disease outcome in elderly patients with diffuse large cell lymphoma (DLCL) treated with CHOP chemotherapy Leuk Lymphoma, 39, pp. 26-75.
23. Ozer, H and Armitage, J and Bennett, C and (2000) for the American Society of Clinical Oncology Growth Factors Expert Panel. 2000 Update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines J Clin Oncol, 18, pp. 3558-3585.